decreased colonization by the probiotic Faecalibacterium prausnitzii and increase in Escherichia coli. [4] [5] [6] Similar changes have been found in the treatment-naive mucosa-associated microbiome in pediatric CD. 7 CD mucosa-associated E. coli commonly adhere to and invade epithelial cell-lines and are therefore termed adherentinvasive E. coli (AIEC). Although originally isolated from CD ileal mucosa, they are also found in the colon. 5, 7 AIEC taken up by macrophages are initially destroyed within autophagosomes, 8 but some escape this process and replicate within the acidic environment of phagolysosomes. 9 Phagocytosed AIEC induce granuloma formation in vitro 10, 11 and in animal models. 12 This, and the common presence of E. coli DNA in CD-associated granulomas, 11 suggests a possible pathogenic role. AIEC are thought to translocate through microfold cells (M cells) that account for about 5% of the "dome" epithelium overlying Peyer's patches in the distal ileum, and lymphoid follicles in the colon, the sites of the earliest lesions seen in CD. 13, 14 CD AIEC commonly express long polar fimbriae essential for M-cell translocation. 6, 15 Patients with CD commonly have polymorphisms in genes (NOD2/CARD15, IRGM, and ATG16L1) linked to pathogen recognition and autophagy relevant to killing of bacteria within macrophages. 16 CD is also associated with defective recruitment of neutrophils to sites of dermal 17 and mucosal 18 wounding and intradermally injected killed E. coli. 19 Chemotaxis of CD neutrophils is normal when studied ex vivo, [20] [21] [22] and it has been suggested that delayed chemotaxis in vivo results from defective macrophage chemokine release. 19 The delay in neutrophil chemotaxis could then contribute to increased bacterial uptake by macrophages.
CD peripheral blood monocytes have normal ability to kill Gram-positive bacteria, 23 but there has been no published study of their killing of Gram-negative bacteria. This is important not only because of the possible relevance of Gram-negatives such as E. coli in CD pathogenesis but also because macrophages have distinct mechanisms for killing of Gram-negative organisms. This includes interaction with a signaling lymphocyte-activation molecule involved in activation of NADPH oxidase within phagosomes. 24 Proof that intramacrophage E. coli replication may have a pathogenic role in CD will depend on resolution of the disease in response to treatments that target these E. coli. Antibiotic therapy has to date been only modestly effective, 25 possibly either because single antibiotics have been used, with multidrug resistance seen in 61.5% of AIEC, 26 or because some antibiotics, particularly penicillins and gentamicin, are unable to kill bacteria within macrophage vesicles. 27 Macrophages are relatively ineffective at killing bacteria in comparison with neutrophils. 28 In Q-fever and Whipple's disease, where bacteria, Coxiella burnetii and Tropheryma whipplei, respectively, replicate inside macrophage phagosomes, addition of hydroxychloroquine (HCQ) to antibiotics has greatly improved eradication rates. [29] [30] [31] Bacteria, including AIEC, that replicate within macrophage vesicles typically require an acid environment. 9 HCQ is a mild base that is concentrated within intracellular vesicles thus raising their pH. 31 Vitamin D deficiency has been implicated in conditions such as multiple sclerosis and CD that are more common in countries furthest from the equator. 32 Vitamin D is important for normal function of the innate immune system including autophagy and a controlled trial of vitamin D supplementation in CD, regardless of their initial vitamin D status, only just failed (P ¼ 0.06) to significantly reduce relapse. 33 Here, we have assessed the ability of CD monocyte-derived macrophages (MDM) to kill E. coli and to generate a neutrophil chemotactic response. We then assessed the ability of vitamin D and HCQ, at clinically achievable concentrations, to enhance macrophage killing of phagocytosed E. coli.
METHODS

Ethical Considerations
Ethical approval was obtained from the National Research Ethics Service Committee North-West England (study approval number 09/H1010/64) to take peripheral venous blood after informed consent from patients with CD recruited from the Royal Liverpool University Hospital and healthy controls (HC) recruited from Liverpool hospital and University staff.
Bacterial Strains and Culture
Two representative CD mucosa-associated AIEC isolates were studied; HM605, a colonic isolate, 5 and LF82, an ileal isolate. 4 Both isolates replicate within phagolysosomes of murine and human MDM. 9, 27, 34 Laboratory strain E. coli K12 (ATCC 29425; Manassas, VA) and Staphylococcus aureus Oxford stain (NCTC 6571; Public Health England; Porton Down, United Kingdom) were also tested. Isolates were grown overnight on Luria-Bertani (LB) agar at 378C in air, washed 3 times in sterile phosphate-buffered saline pH 7.3 (Life Technologies; Paisley, United Kingdom), and resuspended to an optical density (OD 550 nm ) equivalent to 10 9 bacteria per milliliter.
Murine Macrophage Cell-line Culture J774A.1 murine macrophages (91051511) obtained from the European Collection of Cell Cultures (Porton Down; United Kingdom) were cultured at 378C in RPMI medium supplemented with 10% vol/vol fetal bovine serum, 2 mM glutamine, 50 U/mL penicillin, and 50 mg/mL streptomycin, in a humidified atmosphere of 5% CO 2 per 95% air. Macrophages were passaged by scraping twice weekly, up to passage 19.
Isolation of Human Peripheral Blood MDM and Neutrophils
Peripheral venous blood was taken after informed consent from 10 patients with CD recruited from the Royal Liverpool University Hospital and 10 HC recruited from Liverpool hospital and University staff. Tables, Supplemental Digital Content 1, http://links.lww.com/IBD/A836, for inclusion/exclusion criteria (see Table 1 , Supplemental Digital Content 1, http://links.lww. com/IBD/A836), baseline characteristics (equivalent apart from higher hsCRP in CD) (see Table 2 , Supplemental Digital Content 1, http://links.lww.com/IBD/A836), and patient characteristics (see Table 3 , Supplemental Digital Content 1, http://links.lww. com/IBD/A836). Five patients with CD had active disease (Harvey-Bradshaw Index . 4). None were receiving immunosuppressants, corticosteroids, or anti-tumor necrosis factor (TNF) therapy, and none had features of sepsis (median hsCRP ¼ 5.9 mg/L; range, 1.04-18.3 mg/L) at the time of sampling. Blood (50 mL) was immediately heparinized using unfractionated heparin sodium 5 U/mL (Wockhardt UK Ltd, Wrexham; Wales), mixed 1:1 with phosphate-buffered saline, layered over Lymphoprep (Alere; Stockport, United Kingdom), and centrifuged at 800g for 20 minutes at room temperature. Mononuclear cells were aspirated, washed, resuspended in RPMI supplemented with 20 mM HEPES pH 7.4, 100 U/mL penicillin, and 100 mg/mL streptomycin, adjusted to 5 · 10 6 cells per milliliter and seeded into 100 mm Nunc culture dishes (VWR; Lutterworth, United Kingdom). After 2-hour incubation at 378C, nonadherent cells were removed by washing and adherent monocytes differentiated into macrophages over 5 days. 19 Neutrophils were isolated from heparinized venous blood using Polymorphprep (Alere) according to manufacturer's instructions and, after removal of red cells by hypotonic lysis, resuspended in RPMI with 20 mM HEPES pH 7.4, 0.5% vol/vol bovine serum albumin, 2 mM CaCl 2 , and 2 mM MgCl 2 .
Intramacrophage Bacterial Killing
Ability of human MDM and J774A.1 macrophages to kill phagocytosed bacteria was assessed by a gentamicin protection assay. 27 Macrophage monolayers were inoculated with bacteria at a multiplicity of infection of 25 (for MDM) or 10 (J774.A1). After 2-hour infection, macrophages were washed thrice with sterile phosphate-buffered saline and incubated for 1 hour in RPMI containing 10% vol/vol fetal bovine serum, 2 mM glutamine (for J774.A1) or in X-Vivo 15 (for MDMs), and 20 mg/mL gentamicin to kill adherent, noninternalized bacteria. Macrophages were washed and lysed with 1% vol/vol Triton X-100 for 5 minutes to release internalized bacteria. Bacteria colony-forming units were counted after overnight culture on LB agar. Parallel plates were cultured for a further 3 hours after 1-hour incubation with gentamicin (6 hr in total), again followed by lysis and overnight colony-forming units counting. Data were expressed as fold change of recovered intramacrophage bacteria at 6 hours relative to 3 hours.
Effects of HCQ, with and Without Antibiotics, and Vitamin D on Intramacrophage Survival of CD AIEC Doxycycline and ciprofloxacin were tested at C max (peak serum concentration achieved with standard oral dosing) and 10% C max, based on published data. 35, 36 HCQ concentrations were based on published steady state concentrations. 37 Concentrations of 1,25 OH 2 -vitamin D 3 were those defined as deficient in human serum (,20 nM) 32, 38 and that required for optimal immune cell function (.80 nM).
32,39
Cytokine Enzyme-linked Immunosorbent Assays
Interleukin 6 (IL-6), IL-8, and TNF-a were quantified by enzyme-linked immunosorbent assay as per manufacturer's instructions (R&D systems; Abingdon, United Kingdom; IL-6, D6050; IL-8, D800C; TNF-a, DTA00C). Murine IL-6 and TNF-a released by J774A.1 macrophages were also determined by enzyme-linked immunosorbent assay (R&D systems; IL-6, M6000B; TNF-a, SMTA00B). OD 450 nm was measured using a Sunrise microplate reader (Tecan; Theale, United Kingdom).
Neutrophil Chemotaxis Assay
Neutrophil chemotaxis was quantified using a CytoSelect 96-Well Cell Migration Assay, 3 mm pore diameter (Cambridge Bioscience; Cambridge, United Kingdom) as per manufacturer's instructions. Chemoattractant in the lower chamber was X-Vivo 15 medium from 10 5 MDM either uninfected or infected for 6 hours with E. coli HM605 or K12 (multiplicity of infection of 25). CyQuantGR fluorescence was measured using an F200 microplate reader (Tecan); excitation l 485 nm, emission l 535 nm.
Effect of HCQ on Macrophage Intraphagolysosome pH
J774A.1 macrophages cultured in 35 mm CELLview dishes (Greiner Bio-One; Stonehouse, United Kingdom) were washed and incubated in phenol red-free RPMI containing 10 mg/mL pHrodo-conjugated E. coli bioparticles and HCQ (0-10 mg/mL) for 3 hours at 378C. Imaging was by a Zeiss LSM-510 meta-laser confocal microscope with atmosphere-and temperaturecontrolled stage (Carl Zeiss AG, Oberkochen, Germany). Ten random high-powered fields were imaged for each treatment, processed using LSM-5 software (Zeiss AG), and fluorescence intensity analyzed with AQM-6 (Kinetic Imaging; Nottingham, United Kingdom). A pH-calibration curve was constructed by incubation of pHrodo bioparticle-loaded macrophages with buffers (pH 4-7) containing ionophores nigericin (10 mM) and vanilomycin (10 mM) plus the vacuolar H + -ATPase inhibitor bafilomycin (0.1 mM).
40 NH 4 Cl (2 mM) was used as an intraphagolysosome alkalinization control.
Influence of Intracellular Iron Availability on the Action of HCQ
To determine whether the antibacterial actions of HCQ were mediated through pH-mediated restriction of intramacrophage iron, macrophages were pretreated with either 10 mM ferric citrate, which exhibits pH-dependent solubility and release of free ferric iron, or 10 mM ferric nitrilotriacetic acid (FeNTA), which releases free ferric iron irrespective of pH. 41 Genomic Analysis for CD-associated Polymorphisms in NOD2/CARD15, ATG16L1, and IRGM Genomic DNA was extracted using a Nucleon BACC3 kit (Gen-Probe; Livingston, United Kingdom) from EDTA-treated peripheral venous blood taken from patients with CD and HC in whom macrophage function studies were also performed. DNA yield was determined using PicoGreen (Life Technologies), and samples normalized to 10 ng/mL. Single nucleotide polymorphisms were analyzed by TaqMan quantitative polymerase chain reaction for NOD2/CARD15 (rs2066844, rs2066845, and rs2066847), ATG16L1 (rs2241880), and IRGM (rs13361189). 42 
Cytotoxicity Assay
Macrophage viability was assessed by measuring release of intracellular adenylate kinase into supernatants over 6 hours after drug treatments and/or bacterial infection using the ToxiLight bioassay kit as per manufacturer's instructions (Lonza; Slough, United Kingdom). Luminescence was measured on a Tecan F200 microplate reader.
Statistical Analysis
N indicates number of patients or independent experiments performed with cells seeded in triplicate for each experiment. Sample groups were assessed for normality and equality of variances. Comparison of CD patient data versus HC was by Mann-Whitney U test. Dose-response experiments were analyzed using Cuzick's test for trend, followed, where significant, by Dunnett's test. Other multiple treatment experiments were analyzed using one-way analysis of variance followed by selected pair-wise comparison of treatment means (StatsDirect; Sale, United Kingdom). Differences were considered significant when two-tailed, P , 0.05. (Fig. 1 ). There was a nonsignificant trend toward increased intramacrophage replication of HM605 among patients with CD with active disease (mean fold replication ¼ 1.74 [95% CI, 0.67-2.81]) compared with those with inactive disease (mean ¼ 0.43 [95% CI, 0.0-0.87], P ¼ 0.10), but replication of HM605 in patients with active disease was similar to that seen in HC (Fig. 2) . No correlation was seen between the total number of affected NOD2/CARD15 and ATG16L1 alleles and ability to kill intramacrophage HM605, but none of the patients with CD studied were homozygous for affected NOD2/CARD15 or IRGM alleles, and only 1 was homozygous for affected ATG16L1 (Fig. 2) . (Fig. 3) . No significant difference was seen in the chemotactic response generated by MDM derived from patients with active CD compared with those with inactive disease (P ¼ 0.60) (see Table 3 
RESULTS
MDM from HC and
Patients with CD Have Equivalent Ability to Generate Neutrophil Chemoattractants in Response to E. coli HC and CD E. coli-infected MDM were more able to induce neutrophil chemotaxis than uninfected MDM but with no significant difference between CD (N ¼ 10 patients) and HC (N ¼ 7
HCQ Enhances Intramacrophage Killing of AIEC in Murine and Human Macrophages
HCQ induced a dose-dependent enhancement of intracellular killing of HM605 by J774A.1 macrophages (P , 0.001, Cuzick's test for trend). Net replication of E. coli (mean fold replication over 3 hr: 3.59 6 0.35) occurred in the untreated control, but, at concentrations of HCQ at $2 mg/mL, net killing of E. coli occurred (Fig. 4A) . Similar results were obtained with nonhydroxylated chloroquine (see Fig, Supplemental Digital Content 2, http://links. lww.com/IBD/A837). HCQ also induced dose-dependent enhancement of intracellular killing of HM605 in human MDM (P , 0.001, Cuzick's test) (Fig. 4B) . It should be noted that HCQ, up to 10 mg/mL, showed no significant direct effect on growth of HM605 in broth over 7 hours monitored at OD 600 nm (Fig. 4C) and by colony-forming units on LB agar (see 
HCQ Raises Phagolysosomal pH and Alters Intracellular Iron Metabolism
Addition of HCQ to HM605-infected J774A.1 macrophages caused a dose-dependent increase in phagolysosomal pH (N ¼ 6, P , 0.005, Cuzick's test). From a baseline of 5.21 6 0.31 (mean 6 SEM), pH increased stepwise to 5.56 6 0.36 at HCQ 5 mg/mL and 7.25 6 0.47 at 10 mg/mL (Fig. 5) .
Cotreatment with the iron substrates, ferric citrate (allowing pH-dependent release of ferric iron) and FeNTA (allowing release of ferric iron irrespective of pH), only partially reversed the effect of HCQ, with a significant but partial effect seen only at 5 to 10 mg/mL HCQ (Fig. 5) .
A modest trend toward increased cathepsin G (P ¼ 0.03, Cuzick's test) and macrophage elastase MMP12 (P ¼ 0.04) activity was seen in whole cell lysates of HM605-infected macrophages treated with HCQ (see Data, Supplemental Digital Content 4, http://links.lww.com/IBD/A839). 
HCQ Enhances the Antimicrobial Effect of Doxycycline and Ciprofloxacin Against AIEC Replicating Within Macrophages
Doxycycline at 10% C max was ineffective at killing intramacrophage HM605 (89.01% 6 8.57%, mean% 6 SEM% survival relative to control, P ¼ 0.08) and only achieved modest decreases in viable bacteria at C max (75.5% 6 6.72%, P , 0.01). However, at both 10% C max (48.9% 6 5.36%, P , 0.001) and C max (34.49 6 4.71, P , 0.001), cotreatment with HCQ plus doxycycline led to significant enhancement of bacterial killing relative to control and was also significantly more effective than antibiotic monotherapy (P , 0.001 at both 10% C max and C max ; N ¼ 6). (Fig. 6) .
Ciprofloxacin effectively killed intramacrophage HM605 at 10% C max (4.95% 6 0.92%, mean% 6 SEM% survival relative to control, P , 0.001) and led to near complete killing at C max (0.2% 6 0.0%, P , 0.001). Combination of HCQ with ciprofloxacin was more effective than antibiotic monotherapy at 10% C max (2.8% 6 0.82%, P , 0.05), but at C max , no additional effect was seen (0.3% 6 0.1%, P ¼ 0. 
DISCUSSION
Here, we show that MDM from healthy individuals are ineffective at killing CD mucosally derived AIEC, but that CD MDM are similarly ineffective. Moreover, the CD MDM show no defect in generation of neutrophil chemoattractants in response to E. coli. Since E. coli replicating within macrophage phagolysosomes represent a plausible therapeutic target in CD, and are likely to be relatively resistant to antibiotic therapy, we investigated the effects of HCQ and 1,25 OH 2 -vitamin D 3 on killing of CD E. coli by macrophages. Both HCQ and 1,25 OH 2 -vitamin D 3 are shown to greatly enhance the ability of macrophages to kill phagocytosed E. coli. The effect of HCQ is synergistic with antibiotics, suggesting a plausible new approach to therapy.
Defective neutrophil chemotaxis has been consistently reported in patients with CD. Neutrophils are usually plentiful in CD tissue sections, but it has been suggested that a delayed neutrophil response to an initial bacterial attack may result in bacteria being taken up by macrophages before the neutrophils arrive. 18 These macrophages, being much less effective than neutrophils at killing phagocytosed bacteria, may then become chronically infected, resulting in granuloma formation. It has been suggested that the decreased in vivo neutrophil chemotaxis seen in CD may be due to a defective macrophage chemokine response to bacterial triggers. 19 Studies have shown defective secretion of IL-8 by CD MDM in response to the NOD2 ligand muramyl dipeptide 18 and into CD blister fluid. 43 In the latter study, blister fluid concentrations of IL-8, but not those of TNF-a or other cytokines, correlated with decreased chemotaxis. However, subsequent studies of CD MDM have shown decreased secretion of TNF-a and other cytokines but not IL-8. 19, 44 Here, CD peripheral blood MDM behaved similarly to those from HC in their ability to generate neutrophil chemoattractants in response to E. coli; their E. coli-induced secretion of IL-8, TNF-a, and other cytokines was also similar. A defective macrophage cytokine response has previously been reported in individuals who are homozygous or compound heterozygous for altered NOD2/CARD15 alleles, 18, 44, 45 but this genotype is only present in around 8% of CD and was not present in any patients in our study. The mechanism underlying the defective neutrophil chemotaxis seen in vivo in the majority of patients with CD is therefore still unclear, but the presence of circulating chemotaxis inhibitors remains a possibility. [46] [47] [48] Peripheral blood MDM from patients with CD have previously been shown to be normal in their ability to kill phagocytosed S. aureus. 23 Given the different mechanisms involved in killing of Gram-negative organisms by macrophages, it was important also to assess the ability of CD macrophages in killing AIEC. It is shown here that even healthy macrophages are ineffective at killing phagocytosed E. coli including AIEC but that CD macrophages are no worse. It has recently been shown that MDM from patients with CD, homozygous for the ATG16L1 risk allele show impaired killing of phagocytosed AIEC when studied in the presence of phorbol ester to mimic inflammatory conditions. 49 Only 1 of the patients in this study was homozygous for the ATG16L1 risk allele.
The mechanisms by which microbes evade intramacrophage killing include resistance to pH changes, prevention of phagosomal maturation, escape into the cytosol, and resistance to reactive oxygen species. 50, 51 This is typified by C. burnetii, the agent of Q-fever, which is adapted to survive at the acidic pH within macrophage phagolysosomes. 52, 53 Although CD AIEC isolates, such as LF82, are rapidly attacked through the autophagocytic pathway, 8 some can escape autophagy and then survive and, like C. burnetii, replicate within mature phagolysosomes, which provide them with the acidic pH necessary for their replication. 9 The survival of C. burnetii within macrophages is substantially decreased in vitro by HCQ treatment and this translated into clinical response in a randomized trial. 54 Similar effects have been seen for HCQ against T. whipplei, the causative organism of Whipple's disease and a combination of doxycycline and HCQ is now recommended as first-line therapy. 55 This study shows a marked effect of HCQ on survival of phagocytosed AIEC within macrophages, similar to that previously shown for chloroquine 9 and probably mediated largely by increased intravacuolar pH.
We have shown here that HCQ, at concentrations that should be achievable in vivo, has a marked synergistic effect with antibiotics, such as ciprofloxacin and doxycycline that are effective against intracellular E. coli. HCQ has not proved effective when used, mainly on the basis of its anti-inflammatory effects, as a single agent in CD, 56 although it has been successfully used in the treatment of chronic granulomatous disease, an inherited condition associated with defective neutrophil function, impaired NADPH oxidase freeradical production and granulomatous colitis that mimics CD. 57 Eradication of E. coli replicating within tissue macrophages, in analogy with the causative organisms of Whipple's disease and Q-fever, will almost certainly require that HCQ is combined with appropriate antibiotics. This approach has a proven safety record even with longterm treatment. 58 In view of the associations between CD and polymorphisms in genes such as NOD2/CARD15, ATG16L1, and IGRM, all of which impact on autophagy, it has been suggested that stimulation of autophagy would be a plausible therapeutic strategy. 8 It might therefore seem counterintuitive to consider a drug such as HCQ FIGURE 6 . HCQ enhances antibiotic efficacy against intramacrophage AIEC. Combination therapy (antibiotic plus HCQ, 1 mg/mL) was more effective at killing AIEC HM605 within J774.A1 macrophages than antibiotic monotherapy at (A) 10% C max doxycycline and (B) C max doxycyline [2 mg/mL]; N ¼ 6. Likewise, for (C) 10% C max ciprofloxacin. D, No additional benefit was seen with ciprofloxacin at C max [4 mg/mL]; N ¼ 3. *P , 0.05, ***P , 0.001, ***P , 0.001; analysis of variance.
that, like other quinolone antimalarials, inhibits the late stages of autophagy, particularly fusion of autophagosomes with lysosomes. 59 This effect is dose-dependent, however, and it has been reported that chloroquine may even enhance fusion at lower concentrations. 60 In support of this, it has been shown to inhibit intramacrophage replication of Mycobacterium tuberculosis and to enhance the antituberculosis protectiveness of both isoniazid and 25 OH-vitamin D 3 . 61 Moreover CD-derived AIEC can replicate within phagolysosomes, having escaped autophagy, 9 whereas rapamycin, which stimulates autophagy, becomes ineffective once intramacrophage replication of AIEC has become established. 8 Vitamin D has been shown to be important to autophagy and other aspects of the innate immune response. 32, 39, 62 We have shown here that vitamin D, also at concentrations readily achievable with oral supplementation, substantially enhances the ability of human MDM to kill phagocytosed E. coli. There is clear justification for further studies of vitamin D supplementation in CD.
It can currently still be argued that the increase in mucosally associated E. coli commonly found in CD may be a secondary phenomenon. Proof of the direct involvement of E. coli in CD pathogenesis now depends on showing that a therapy targeted against E. coli replicating within macrophages can induce remission in CD. A controlled trial of combination ciprofloxacin/ doxycycline/HCQ therapy in active CD has therefore been commenced (ClinicalTrials.gov NCT01783106).
